

Redsense Medical AB valberednings motiverande yttrande avseende förslag till årsstämman 2026 samt en redogörelse för hur valberedningen har bedrivit sitt arbete

Redsense Medicals valberedning inför årsstämman 2026 konstituerades baserat på ägarförhållandena i bolaget per den 30 september 2025.

Valberedningen har bestått av Susanne Olauson, utsedd av Seventh Sense Adventures Holding AB, Johannes Köpple, utsedd av ShapeQ GmbH, Oscar Bergman, utsedd av Swedbank Robur Fonder AB. Susanne Olauson utsågs till valberedningens ordförande. Ingen ersättning har utgått till valberedningens ledamöter.

Aktieägare har haft möjlighet att lägga fram förslag till valberedningen via e-post, inga sådana förslag har inkommit.

Valberedningens förslag till årsstämman den 20 maj, 2026

Valberedningen föreslår att Susanne Olauson utses till stämмоordförande.

Valberedningen föreslår att styrelsen ska bestå av fem ledamöter utan suppleanter.

Valberedningen föreslår omval av Mike Griffiths, Johannes Köpple, Susanne Olauson och Martin Roos. Valberedningen föreslår att Michael A Kraus väljs in som ny styrelseledamot.

Michael A Kraus is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief Medical Officer at NxStage Medical and Fresenius Kidney Care. Dr. Kraus is a recognized leader in CRRT, home dialysis, and ESKD care, with extensive experience in patient care, administration, and government relations. He has authored numerous manuscripts and book chapters and is an internationally recognized speaker.

Michael holds an AB degree from Wabash College, MD from Indiana University, Indianapolis Indiana. Other assignments are Chief Medical Director at Indiana Donor Network (Organ Procurement Organization) Emeritus Professor of Clinical Medicine – Indiana University School of Medicine

Michael Kraus är oberoende gentemot bolaget och dess ledning samt större aktieägare.

Valberedningen föreslår dessutom att Susanne Olauson väljs till ordförande i styrelsen för det kommande året.

Valberedningen har tillämpat regel 4.1 i Svensk kod för bolagsstyrning vid framtagande av förslaget till styrelse. Valberedningen anser att det bland de

föreslagna styrelseledamöterna finns en mångfald och bredd vad gäller utbildningsbakgrund, erfarenhet, kompetens och tid de innehåft uppdraget. Valberedningen anser att det är angeläget att framtida valberedningar fortsatt arbetar aktivt med att bidra till ökad mångfald i styrelsen.

Den föreslagna styrelsen lever upp till kraven på oberoende i Svensk kod för bolagsstyrning.

Mer information om de personer som föreslås för val till styrelsen finns på bolagets webbplats www.redsensemedical.com.

Valberedningens föreslår omval av revisor Andreas Johansson, Azets Revision & Rådgivning AB.

Som arvode till styrelsen för tiden intill dess att årsstämma 2027 har hållits föreslås 250 000 kronor till styrelsens ordförande och 125 000 kronor vardera till styrelseledamöter. Arvodet föreslås därmed vara oförändrat. Vid utvärdering av arvodena har en jämförelse gjorts avseende arvoden i bolag av liknande storlek och komplexitet gjorts. Mot denna bakgrund bedömer valberedningen att den föreslagna nivån är rimlig och väl motiverad. Arvode till revisorn föreslås utgå löpande, under revisorns mandattid, enligt godkänd räkning.

Valberedningen har granskat gällande valberedningsinstruktion, vilken antogs av stämman 2021 och har beslutat att inte föreslå någon uppdatering av denna.

Valberedningens konstituerades den 20 oktober 2025 och sammansättningen offentliggjordes samma dag. Valberedningen har därefter haft fem digitala arbetsmöten. Därutöver har valberedningen haft flera kontakter per telefon och mail. Samtliga styrelseledamöter och bolagets verkställande direktör har intervjuats. Valberedningen har under processen utvärderat vilka ytterligare kompetenser som behövs i styrelsen. Förslag till inval av en ny styrelseledamot avser att fylla detta kompetensbehov. Valberedningens beslut avseende förslaget till stämman var enhälligt.

Halmstad i april 2026

Valberedningen i Redsense Medical AB (publ)

Redsense Medical AB Nomination Committee's motivational statement regarding proposals for the 2026 Annual General Meeting and a report on how the Nomination Committee has conducted its work

Redsense Medical's Nomination Committee for the 2026 Annual General Meeting was constituted based on the ownership structure in the company as of September 30, 2025.

The Nomination Committee consisted of Susanne Olauson, appointed by Seventh Sense Adventures Holding AB, Johannes Köpple, appointed by ShapeQ GmbH, Oscar Bergman, appointed by Swedbank Robur Fonder AB. Susanne Olauson was appointed as the Chair of the Nomination Committee. No remuneration has been paid to the members of the Nomination Committee.

Shareholders have had the opportunity to submit proposals to the Nomination Committee via email, no such proposals have been received.

Nomination Committee's proposal for the Annual General Meeting on May 20, 2026

The Nomination Committee proposes that Susanne Olauson be appointed as Chair of the Meeting.

The Nomination Committee proposes that the Board shall consist of five members without deputies.

The Nomination Committee proposes the re-election of Mike Griffiths, Johannes Köpple, Susanne Olauson and Martin Roos. The Nomination Committee proposes Michael A Kraus to be elected as a new Board member.

Michael A Kraus is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief Medical Officer at NxStage Medical and Fresenius Kidney Care. Dr. Kraus is a recognized leader in CRRT, home dialysis, and ESKD care, with extensive experience in patient care, administration, and government relations. He has authored numerous manuscripts and book chapters and is an internationally recognized speaker.

Michael holds an AB degree from Wabash College, MD from Indiana University, Indianapolis Indiana. Other assignments are Chief Medical Director at Indiana Donor Network (Organ Procurement Organization) Emeritus Professor of Clinical Medicine – Indiana University School of Medicine.

Michael A Kraus is independent of the company and its management and major shareholders.

The Nomination Committee also proposes that Susanne Olauson be elected Chair of the Board for the coming year.

The Nomination Committee has applied Rule 4.1 of the Swedish Code of Corporate Governance when preparing the proposal for the Board. The Nomination Committee believes that the proposed Board members represent a diversity and breadth in terms of educational background, experience, competence and length of time they have held the position. The Nomination Committee believes that it is important that future Nomination Committees continue to work actively to contribute to increased diversity on the Board.

The proposed board meets the requirements for independence in the Swedish Code of Corporate Governance.

More information about the persons proposed for election to the board can be found on the company's website www.redsensemedical.com.

The Nomination Committee proposes the re-election of auditor Andreas Johansson, Azets Revision & Rådgivning AB.

As a fee to the board for the period until the 2027 Annual General Meeting has been held, SEK 250,000 is proposed for the chairman of the board and SEK 125,000 each for the board members. The fee is therefore proposed to remain unchanged. When evaluating the fees, a comparison has been made regarding fees in companies of similar size and complexity. Against this background, the Nomination Committee considers that the proposed level is reasonable and well justified. It's proposed that the auditor's fee be paid on an ongoing basis, during the auditor's term of office, according to an approved invoice.

The Nomination Committee has reviewed the current Nomination Committee instructions, which were adopted by the 2021 AGM, and has decided not to propose any updates to them.

The Nomination Committee was constituted on October 20, 2025 and its composition was announced on the same day. The Nomination Committee has since held five digital working meetings. In addition, the Nomination Committee has had several contacts by telephone and email. All board members and the company's CEO have been interviewed. During the process, the Nomination Committee has evaluated what additional skills are needed on the board. The proposal to elect a new board member is intended to fill this need for skills. The Nomination Committee's decision regarding the proposal to the meeting was unanimous.

Halmstad, April 2026

The Nomination Committee of Redsense Medical AB (publ)